FK506-binding protein like (FKBPL), an anti-tumour protein that belongs to the family of immunophilins, was shown to inhibit endocrine therapy resistant CD44+ cancer stem cells in ER+ disease, via modulation of the components of the Notch pathway, DLL4 and Notch4 (89). This evidence concerns the gene FKBPL and neoplasm.